Clinical Trials
15 trialsNCT07061977 2026-06-05
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT07188532 2026-06-04
BEAR
Mayo Clinic
Phase NA Recruiting
NCT02306161 2026-06-03
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03786783 2026-06-02
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02466971 2026-05-29
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02595879 2026-05-29
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04423211 2026-05-15
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04214067 2026-05-13
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03070886 2026-05-07
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology
Phase 2/3 Completed
NCT05946213 2026-05-07
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology
Phase 3 Recruiting
NCT06319430 2026-05-05
Technology in Play for Children With Physical Disabilities: the Dice Model of Play
University of Manitoba
Phase NA Recruiting
NCT07189598 2026-04-30
ORION
Center Eugene Marquis
Phase NA Recruiting
NCT03942328 2026-04-20
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
Phase 1/2 Recruiting
NCT02366819 2026-03-30
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
University of Chicago
Phase 4 Suspended
NCT06323460 2026-03-24
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting